MSH2 and cancer: Among first cancer detected in each patient from the first prospective lynch syndrome database, the EC cumulative incidences at 70 years by gene were 34%, 51%, 49% and 24% for MLH1, MSH2, MSH6 and PMS2 mutation carriers, respectively (5).